The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis

被引：0
|
作者：
Borman, Pinar [1 ]
Ayhan, Figen [1 ]
Ceceli, Esma [1 ]
机构：
[1] Ankara Numune Training & Res Hosp, Clin PMR, Ankara, Turkey
来源：
RHEUMATOLOGY INTERNATIONAL | 2010年 / 30卷 / 12期
关键词：
Ankylose Spondylitis; High Disease Activity; Physical Therapy Intervention; Outpatient Unit; Rheumatology Outpatient;
D O I：
10.1007/s00296-009-1283-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1689 / 1690
页数：2
相关论文
共 22 条
  • [1] The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis
    Pinar Borman
    Figen Ayhan
    Esma Ceceli
    Rheumatology International, 2010, 30 : 1689 - 1690
  • [2] Structure-Modifying Capacity of Anti-Tumour Necrosis Factor-α Therapy in Ankylosing Spondylitis
    Filip De Keyser
    Dominique Baeten
    Filip Van den Bosch
    Elli Kruithof
    Gust Verbruggen
    Herman Mielants
    Eric Veys
    Drugs, 2004, 64 : 2793 - 2811
  • [3] Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Joachim Listing
    Jan Brandt
    Martin Rudwaleit
    Joachim Sieper
    Juergen Braun
    Arthritis Research & Therapy, 7
  • [4] A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
    Lucy Edgson
    Robert Field
    Sarah Westlake
    Journal of Foot and Ankle Research, 3 (Suppl 1)
  • [5] The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
    Chamaida Plasencia
    Dora Pascual-Salcedo
    Sara García-Carazo
    Leticia Lojo
    Laura Nuño
    Alejandro Villalba
    Diana Peiteado
    Florencia Arribas
    Jesus Díez
    Maria Teresa López-Casla
    Emilio Martín-Mola
    Alejandro Balsa
    Arthritis Research & Therapy, 15
  • [6] Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    Martin Rudwaleit
    Filip Van den Bosch
    Martina Kron
    Sonja Kary
    Hartmut Kupper
    Arthritis Research & Therapy, 12
  • [7] Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Baraliakos, X.
    Listing, J.
    Brandt, J.
    Rudwaleit, M.
    Sieper, J.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S14 - S14
  • [8] Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    X Baraliakos
    J Listing
    J Brandt
    M Rudwaleit
    J Sieper
    J Braun
    Arthritis Research & Therapy, 7
  • [9] Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Carla GS Saad
    Ana CM Ribeiro
    Julio CB Moraes
    Liliam Takayama
    Celio R Goncalves
    Marcelo B Rodrigues
    Ricardo M de Oliveira
    Clovis A Silva
    Eloisa Bonfa
    Rosa MR Pereira
    Arthritis Research & Therapy, 14
  • [10] Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
    Barallakos, X.
    Brandt, J.
    Listing, J.
    Sieper, J.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S14 - S14
123